Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
Clin Lung Cancer. 2010 Jan;11(1):8-12. doi: 10.3816/CLC.2010.n.001.
Advanced non-small-cell lung cancer (NSCLC) remains a major global health problem. Although the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib improves survival in patients with relapsed and recurrent NSCLC, significant limitations exist, including the restriction of clinical efficacy to a small patient subset, poor survival rates, and the development of resistance. Irreversible inhibitors of EGFR and HER2 are novel agents in clinical development that might have the potential to prevent and overcome acquired resistance to first-generation EGFR inhibitors.
晚期非小细胞肺癌（NSCLC）仍然是一个全球性的重大健康问题。尽管可逆表皮生长因子受体（EGFR）酪氨酸激酶抑制剂厄洛替尼改善了复发和转移性 NSCLC 患者的生存，但仍存在显著的局限性，包括临床疗效局限于一小部分患者、生存率低以及耐药性的发展。EGFR 和 HER2 的不可逆抑制剂是正在临床开发中的新型药物，可能具有预防和克服第一代 EGFR 抑制剂获得性耐药的潜力。
